Overview

A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This study is designed to assess the tolerability of test product and vehicle in terms of skin reactions during repeated topical applications on healthy skin under controlled conditions on the basis of the international guidelines for testing of skin irritations (FDA Guidance for Industry (1999)).

Phase:

Phase 1

Details

Lead Sponsor:

Moberg Pharma AB

Treatments:

Imiquimod